Physician profile
Marc Eller
NPI 1942200688
$7,709.49
in general payments reported to CMS, 2019-2025
57 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $324 · 2021: $1,414 · 2022: $1,127 · 2023: $1,268 · 2024: $1,069 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,960.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,662.35 | 2019-2025 | |
| Novo Nordisk INC | $1,179.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $701.54 | 2019-2025 | Repatha, Otezla, Prolia |
| Pfizer INC. | $676.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $421.90 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $352.34 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.37 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $229.62 | 2022-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $225.08 | 2019-2025 | Entyvio, Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.41 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $163.45 | 2021-2023 | |
| Lilly USA, LLC | $152.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $116.65 | 2019-2021 | |
| Abbott Laboratories | $92.29 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Janssen Biotech, INC. | $83.74 | 2021-2024 | Stelara, Simponi Aria, Remicade |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Eller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.